Visa and AbbVie combine durable competitive advantages ... Visa's market dominance extends beyond traditional credit card payments. The company continues to invest heavily in digital payment ...

Recently, AbbVie raised its quarterly dividend to $1.64 per share from $1.55. Moreover, the company has increased its ...

AbbVie (ABBV) is a top stock for those seeking ... OneMain has transformed into a multi-product lending platform through expansion into credit cards and auto finance. These products diversified ...

Dividend growth investing is a powerful strategy for building lasting wealth. Companies that consistently raise their dividends tend to possess durable competitive advantages, robust cash flows, and ...

AbbVie is a leader in the pharmaceutical ... a double-digit dividend growth rate for several years. The credit and debit card issuer is attracting Millennials and Gen Z consumers.

The bottom line? AbbVie's post-Humira prospects look far better than investors are giving it credit for. The dividend is rock-solid and should continue growing along with the share price over the ...

Per the terms of the deal, AbbVie will use Neomorph's proprietary platform to develop novel drugs targeting oncology and ...

AbbVie (NYSE:ABBV) will report Q4 2024 results next week and provide guidance for 2025. The company is handling the erosion of Humira quite well, but the trajectory of the decline in Humira's net ...

Gifting allows recipients to access the article for free. Pharmaceutical giant AbbVie has inked another collaboration deal with an emerging biotech company as it seeks ways to bulk up its drug ...

Not only did AbbVie’s Skyrizi claim first place in the full-year ranking with nearly $377 million spent on 20 separate ads for the drug, according to iSpot.TV’s analysis, but, with two other ...

Several major credit card companies have cards that offer roadside assistance without an annual membership fee.